Other languages Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq Other stock markets 02:00:00 07/05/2024 am IST			5-day change	1st Jan Change
22.68 ^USD	+0.35%		-3.28%	-19.14%

15/04	Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	MT
12/04	Pharvaris Files Mixed Shelf	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharvaris Narrows Q4 Net Loss; Hires New CFO	11/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	11/04
Pharvaris Says FDA Lifts Clinical Hold on Application for Potential Treatment of Hereditary Angioedema Attacks	22/01
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday	22/01
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	22/01
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks	22/01
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023	09/12
Koersalarm: aandeel Pharvaris blijft stijgen	07/12
Sector Update: Health Care Stocks Mixed Premarket Wednesday	06/12
Sector Update: Health Care	06/12
Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell	06/12
Top Premarket Gainers	06/12
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks	06/12
Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer	15/11
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting	09/11
Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Pharvaris N : Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl	05/23/05
Pharvaris N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07
Pharvaris N.V. Announces Board Changes	03/23/03
Pharvaris Says US FDA Lifts Clinical Hold on IND Application for Hereditary Angioedema Treatment Candidate	26/23/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Other languages

Filters